© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
MASLD/MASH
Semaglutide 2.4 mg Approved for Treatment of MASH Without Cirrhosis: Daily Dose
August 26, 2025
Your daily dose of the clinical news you may have missed.
FDA Approves Semaglutide 2.4 mg for Treatment of MASH Without Cirrhosis
August 16, 2025
The accelerated approval for semaglutide 2.4 mg for the treatment of noncirrhotic MASH was based on part 1 of the phase 3 ESSENCE trial, which met its primary endpoints.
Bariatric Surgery Lowers Risk of Liver Complications in Patients with Cirrhosis, Obesity
January 28, 2025
Metabolic surgery reduced major adverse liver outcomes in people with compensated cirrhosis and obesity by 72%, according to new data.